论文部分内容阅读
长期以来,对呼吸道合胞病毒感染一直缺乏有效的治疗方法和药物,近年来这种状况已有所改观。在对症治疗方面,肾上腺素能支气管扩张剂的疗效已为多数人所肯定。在病因治疗方面,三氮唑核苷、含高滴度呼吸道合胞病毒中和抗体的免疫球蛋白及干扰素等均显示出较好的疗效,尤其是在治疗严重呼吸道合胞病毒感染方面已为人们所公认。上述药物均可通过气雾吸入等途径局部给药,使疗效大为提高,副作用也更少,同时还具有药效发挥迅速、给药方便、经济等优点,日益受到人们推崇。
For a long time, there has been a lack of effective treatments and drugs for respiratory syncytial virus infection, which has changed in recent years. In the symptomatic treatment, the efficacy of adrenergic bronchodilators has been affirmed by the majority. In the cause of treatment, ribavirin, immunoglobulin with high titer of respiratory syncytial virus neutralizing antibody and interferon all showed good curative effect, especially in the treatment of severe respiratory syncytial virus infection For people recognized. These drugs can be inhaled by inhalation and other local routes, so that the effect is greatly improved, fewer side effects, but also has rapid drug efficacy, ease of administration, economic advantages, more and more people are respected.